<DOC>
	<DOCNO>NCT00802737</DOCNO>
	<brief_summary>The purpose trial investigate efficacy safety ofatumumab retreatment maintenance patient chronic lymphocytic leukemia previously respond disease stabilization ofatumumab ongoing trial ( Hx-CD20-406 ) .</brief_summary>
	<brief_title>Efficacy Safety Ofatumumab Retreatment Maintenance Treatment Patients With B-cell Chronic Lymphocytic Leukemia ( CLL )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Has respond ofatumumab treatment ( CR , nPR , PR ) SD least include visit number 14 ( 24 week first infusion ) HxCD20406 trial . Has disease progression visit number 14 ( 24 week first infusion ) Hx CD20 406 trial . Received least eight ofatumumab infusion . Has active CLL indication treatment . Has Eastern Cooperative Oncology Group ( ECOG ) performance status grade 0 , 1 2 . Provides sign informed consent , follow receipt verbal write information trial , trial related activity carry . If previously treat GEN416 ( trial ) , patient must achieve CR subsequent disease progression 24 week later first infusion GEN416 trial . The disease transform aggressive Bcell malignancy ( e.g . diffuse large Bcell lymphoma , Richter 's syndrome prolymphocytic leukemia ) . Has suspect treatment require malignancy CLL . Has receive treatment ofatumumab within two week prior visit 2 . Has clinically significant cardiac disease include unstable angina , acute myocardial infarction within six month visit 1 , congestive heart failure ( NYHA III IV ) , arrhythmia require therapy , exception clinically nonsignificant extra systole minor conduction abnormality . Has significant concurrent , uncontrolled medical condition include , limited , renal , hepatic , hematological , gastrointestinal , endocrine , pulmonary , neurological , cerebral psychiatric disease . Has history significant cerebrovascular disease . Is know HIV positive . Has positive serology hepatitis B , define positive test HBsAg and/or positive test antiHBs antiHBc . Has know suspect hypersensitivity component IMP . Has receive treatment nonmarketed drug substance experimental therapy ofatumumab within four week prior visit 2 . Currently participate interventional clinical trial HxCD20406 . Known suspect able comply trial protocol ( e.g . due alcoholism , drug dependency psychiatric disorder ) . Is breast feeding ( woman ) . Has positive pregnancy test screening ( woman ) . Is willing use adequate contraception trial one year last dose ofatumumab ( woman ) . Adequate contraception define hormonal birth control intrauterine device . For patient US use double barrier method consider adequate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Maintenance</keyword>
	<keyword>Retreatment</keyword>
	<keyword>Chronic lymphocytic leukemia</keyword>
	<keyword>B-Cell Chronic Lymphocytic Leukemia</keyword>
	<keyword>Ofatumumab</keyword>
</DOC>